Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

News In Brief

This article was originally published in The Gray Sheet

  • News

Executive Summary

InSightec submits ExAblate PMA to treat pain caused by bone metastases. AngioDynamics initiates NanoKnife software recall. Sequenom raises $62 million in secondary stock offering. More news briefs.

You may also be interested in...



Trial Investigates Focused Ultrasound For Parkinson's Disease Tremor

Clinicians discuss a feasibility trial of InSightec's focused ultrasound technology to reduce tremor related to Parkinson’s disease and a registry to show the effectiveness of focused ultrasound in treating uterine fibroids.

News In Brief

Medtronic opens Shanghai innovation center. Justice Department ICD investigation nears resolution. BD buys dye maker Sirigen. More news briefs.

New Products In Brief

Sequenom’s Down syndrome test

Table

View full table

Related Content

Medtech Insight
Medtech Insight

Topics

Related Companies

Tags:
Medical Device
Latest Headlines

EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions

UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026

Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round

Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children

See All
UsernamePublicRestriction

Register

MT030923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By